A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF REGN7508, A MONOCLONAL ANTIBODY AGAINST FXI, FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I)

Registry ID

R7508-CAT-2392

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

REGENERON PHARMACEUTICALS INC

Last update

2026-07-30

Conditions

• THROMBOSIS

Related clinical trials

• THE IMPACT OF ADDITIONAL POST-OPERATIVE DOSES OF TRANEXAMIC ACID ON PAIN, MOBILITY AND BLEEDING FOLLOWING TOTAL HIP AND TOTAL KNEE ARTHROPLASTY: A RANDOMIZED CONTROLLED TRIAL
• COLCHICINE TO QUENCH THE INFLAMMATORY RESPONSE AFTER DEEP VEIN THROMBOSIS: A RANDOMIZED CONTROLLED PILOT TRIAL (THE CONQUER-DVT PILOT TRIAL)
• A NEW ANTICOAGULATION METHOD USING DALTEPARIN IN QUOTIDIAN AND NOCTURNAL HOME HEMODIALYSIS PATIENTS: A PROSPECTIVE STUDY
• A PILOT FEASIBILITY AND SAFETY MULTICENTER TRIAL OF ADMINISTERING WEIGHT ADJUSTED FIEXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES WITH THROMBOSIS (FIXET): STUDY PROTOCOL

View on source registry